Eli Lilly’s planned acquisition of Adverum Biotechnologies is a noteworthy move in the biopharmaceutical industry—one that signals Lilly’s expanding focus on gene therapies and its ambition to redefine care in ophthalmology. This analytical blog unpacks the deal, its clinical and commercial context, and the wider implications for innovation—and competition—in eye disease therapeutics.
Eli Lilly and Adverum: Strategic Overview
Eli Lilly announced in October 2025 that it will acquire Adverum Biotechnologies for up to $261.7 million, aimed principally at gaining Adverum’s late-stage gene therapy candidate, Ixo-vec, for the treatment of wet age-related macular degeneration (wAMD). The deal consists of an upfront $3.56 per share cash offer, plus a contingent value right (CVR) of up to $8.91 per share tied to regulatory and commercial milestones, totaling a potential $12.47 per share. This aligns with Lilly’s recent moves in one-time therapies and expands its reach in genetic medicine and eye care.[1][2][3][4][5]
Free Membership Required
You must be a Free member to access this content.
